MultiCare, Samaritan combination to close in November
The nonprofits will merge on Nov. 1 after securing approval from state regulators, the systems announced this week.
MultiCare, Samaritan combination to close in November Read More »
Uncategorized
Centene joins insurers waiving prior authorizations for top providers
Centene is the latest insurer to adopt a gold card program as states and the Trump administration push for prior authorization reform.
Centene joins insurers waiving prior authorizations for top providers Read More »
Siemens Healthineers to stop selling general ultrasound systems
In a strategy shift, the company will invest in its procedural ultrasound business, supporting cardiovascular surgeries
Siemens Healthineers to stop selling general ultrasound systems Read More »
Verastem reports ‘robust’ response rate in pancreatic cancer subgroup where Rasonque struggled
Revolution Medicines’ recently approved drug showed a 24% overall response rate and a high rate of side effects in patients whose cancer has a G12D mutation, reinforcing Mizuho’s view that a more specific agent such as Verastem Oncology’s VS-7375 “should come first for G12D patients.”
Gilead snags equity stake in Vir with up to $1.87B deal for three T cell engagers
The Gilead Sciences deal, which include $135 million in upfront and near-term payments, marks a critical platform validation for Vir Biotechnology as investors await an upcoming readout in solid tumors.
Gilead snags equity stake in Vir with up to $1.87B deal for three T cell engagers Read More »
Zealand pens up to $1.2B deal with Generate for AI-designed obesity, metabolic drugs
Obesity-focused Zealand Pharma is buying into Generate:Biomedicines’s generative AI platform to create new multispecific drug candidates.
Zealand pens up to $1.2B deal with Generate for AI-designed obesity, metabolic drugs Read More »
Verdiva ends mid-stage study of oral GLP-1 amid ‘market evolution’
The candidate is an oral version of ecnoglutide, a subcutaneous formulation of which is approved in China for type 2 diabetes and weight management. Pfizer owns commercialization rights for ecnoglutide in the Asian country.
Verdiva ends mid-stage study of oral GLP-1 amid ‘market evolution’ Read More »
J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback
Johnson & Johnson beat analyst expectations in the third quarter but left Wall Street wanting more; BMS dominated the news cycle on Monday with a Phase 3 win validating its $4.1 billion RayzeBio buy and mixed data in a late-stage pulmonary fibrosis trial; Revolution Medicines’ newly approved pancreatic cancer drug works better for patients with
J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback Read More »
Del plano al edificio inteligente: cómo BIM y Revit están transformando la construcción
La digitalización está cambiando la forma de diseñar, construir y gestionar edificios. Frente a los planos tradicionales, la metodología BIM permite trabajar con modelos digitales que reúnen información sobre los distintos elementos de un proyecto. …
Del plano al edificio inteligente: cómo BIM y Revit están transformando la construcción Read More »
Las passkeys avanzan y dejan atrás la contraseña
Cinco mil millones de passkeys estaban ya en uso activo en 2026, mientras el 75% de los consumidores encuestados había habilitado al menos una. El salto dejó de ser experimental y ganó otro respaldo en agosto, cuando WebAuthn Level 3 pasó a ser una recomendaci&o …
Las passkeys avanzan y dejan atrás la contraseña Read More »